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SResults: PPI was required in 173 of 1965 (8.8%) patients. Those with PPI had more
frequent prior chest wall radiation (5.2% vs 2.4%, p¼0.04); baseline EKG ﬁndings
of bradycardia (sinus, sinus pauses, or junctional)(4.1% vs 1.2%, p¼0.01), right
bundle branch block (RBBB)(45.9% vs 12.6%, p<0.001), and left anterior fascic-
ular block (15.9% vs 7.3%, p<0.001); and Echo ﬁndings of smaller left ventricular
(LV) end-diastolic dimension (4.26 cm vs 4.43 cm, p¼0.05) and LV outﬂow tract
(LVOT) diameter (1.97 cm vs 2.01 cm, p¼0.03), and larger ratio of annulus to
LVOT diameter (1.08 vs 1.06, p¼0.006) and prosthesis to LVOT diameter (1.23 vs
1.21, p¼0.001). By multivariable analysis, independent predictors of PPI included
prosthesis/LVOT diameter (OR 11.0, p¼0.003), RBBB (OR 6.2, p<0.001), and
bradycardia (OR 3.6, p¼0.018). At 1 year, PPI was associated with repeat hospi-
talization (24.7% vs 18.6%, p¼0.03), but not with mortality (26.7% vs 21.6%,
p¼0.11), cardiovascular mortality (15.1% vs 13.4%, p¼0.59), stroke (3.5% vs 5.9%,
p¼0.27), or myocardial infarction (2.4% vs 1.8%, p¼0.93). There were no signiﬁ-
cant differences in LV ejection fraction (EF), LV end-systolic dimension, or heart
failure symptoms (NYHA class) at 1 year.
Conclusions: PPI was required in 8.8% of patients without prior PPI undergoing
TAVR with a balloon-expandable valve. Independent predictors of PPI included the
ratio of valve prosthesis diameter to LVOT diameter, baseline RBBB, and brady-
cardia. PPI was not associated with major adverse cardiovascular events or differences
in LV function at 1 year.
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Background: Implantation of a transcatheter valve into a degenerated bioprosthesis
during aortic valve-in-valve procedure (VinV) might signiﬁcantly reduce the
effective oriﬁce area (EOA) available for blood ﬂow. We sought to investigate the
impact of prosthesis-patient mismatch (PPM) on hemodynamics and survival in
these patients.
Methods: Two hundred and twenty data sets of aortic VinV procedures from the
Global Valve-in-Valve Registry were investigated. Severe PPM was deﬁned as an
indexed EOA < 0.65cm2/m2 patient body surface area (BSA).
Results: Severe PPM was present in 70 patients after aortic VinV implantation
(31.8%, age 80  9.4 years, 60% men). The incidence of severe PPM was higher in
patients who received a SAPIEN device vs. a CoreValve (43.8% vs. 15.2%,
p<0.0001). Patients with severe PPM had larger body weight (80.6  16 kg vs. 72.4
 15.1, p¼0.0003), larger BSA (1.94  0.23 m2 vs. 1.82  0.22, p<0.0001), higher
aortic mean gradient after the procedure (20.7  9.2 mmHg vs. 13.8  7.2) and lower
aortic valve area (1.03  0.19 cm2 vs. 1.62  0.44), in comparison with patients
without severe PPM. In patients who survived aortic VinV implantation procedure,
one-year survival was not affected by having severe PPM (86.7% vs. 89.1% in
patients without severe PPM, log rank p¼0.69).
Conclusions: Severe PPM is common after aortic VinV implantation, occurring in
approximately one-third of patients and more frequently after SAPIEN device
implantation. Despite higher valve gradients in patients with severe PPM, one-year
survival was similar to those without severe PPM.B38 JACC Vol 62/18/Suppl B j OctoTCT-117
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Background: In the randomized PARTNER trial of transcatheter aortic valve
replacement (TAVR) for high-risk aortic stenosis, TAVR via the transapical (TA)
approach was associated with worse health-related quality of life (HRQOL) in the
short-term compared with surgical aortic valve replacement (SAVR). Since
PARTNER A represented the ﬁrst TA-TAVR procedures for many study sites, it is
possible that results have improved with greater experience. We therefore examined
HRQOL after TA-TAVR in the non-randomized continued access registry (NRCA) of
the Edwards-Sapien valve and compared these outcomes with patients from the
randomized controlled trial (RCT).
Methods: Patients undergoing TA-TAVR in the NRCA of the Edwards Sapien
valve underwent standardized health status assessments using the Kansas City
Cardiomyopathy Questionnaire (KCCQ), the Short Form-12 (SF-12), and the Euro-
Qol-5D (EQ-5D) at baseline, 1 month (m), 6 m, and 12 m after TAVR. Post-procedure
health status outcomes were compared with those of the TA cohort of the PARTNER
RCT who were treated with either TA-TAVR or SAVR.
Results: Among NRCA TA-TAVR patients with evaluable data, the overall KCCQ
summary score increased by 12.6 points at 1 m (n¼704), 25.8 at 6 m (n¼608), and
25.1 at 12 m (n¼504) (p<0.001 for all compared with baseline). Compared with
RCT-TA patients, there were no signiﬁcant differences in HRQOL at 12 m, but there
were trends toward greater improvements at 1 and 6 m. Compared with RCT-SAVR
patients, there were no signiﬁcant differences in health status outcomes at any
follow-up timepoints (mean difference in KCCQ Overall Summary Score adjusted
for baseline: -1.8 at 1 m, -3.8 at 6 m, 1.8 at 12 m; all p¼NS). Similar results were
seen for the SF-12 physical (0.9 at 1 m; -1.1 at 6 m; 0.2 at 12 m; all P¼NS) and
mental (-1.4 at 1 m; -0.3 at 6 m; -0.9 at 12 m; all P¼NS) component summary
scores.
Conclusions: Improvements in both disease speciﬁc and generic health status among
patients in the NRCA cohort undergoing minimally invasive TA-TAVR with the
Sapien valve were similar to (but not better than) those of SAVR as performed within
the randomized PARTNER trial.
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Background: TAVR is an acceptable alternative to surgery in high risk patients;
however, complications and cost currently limit expansion into lower risk pop-
ulations. Although mortality, vascular injury, stroke, paravalvular regurgitation and
length of stay (LOS) are expected to improve, we sought to determine ifber 27–November 1, 2013 j TCT Abstracts/ORAL/TAVR - Outcomes
